Contagion, December 2020 (Vol. 05 No. 06)

An expert panel discussion around long-acting injectables' role in both preventing and treating HIV.

Biologics have become a novel treatment in recurrent C. difficile.

Since late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.

Fostemsavir, an HIV-1 attachment inhibitor, is a novel therapeutic option for multidrug-resistant HIV. It represents the first oral agent developed for this indication in over a decade and provides promise for patients with limited remaining treatment options.